Meta-analysis of randomized controlled trials on magnesium in addition to beta-blocker for prevention of postoperative atrial arrhythmias after coronary artery bypass grafting

BMC Cardiovascular Disorders (Impact Factor: 1.88). 01/2013; 13(1):5. DOI: 10.1186/1471-2261-13-5
Source: PubMed


Atrial arrhythmia (AA) is the most common complication after coronary artery bypass grafting (CABG). Only beta-blockers and amiodarone have been convincingly shown to decrease its incidence. The effectiveness of magnesium on this complication is still controversial. This meta-analysis was performed to evaluate the effect of magnesium as a sole or adjuvant agent in addition to beta-blocker on suppressing postoperative AA after CABG.

We searched the PubMed, Medline, ISI Web of Knowledge, Cochrane library databases and online clinical trial database up to May 2012. We used random effects model when there was significant heterogeneity between trials and fixed effects model when heterogeneity was negligible.

Five randomized controlled trials were identified, enrolling a total of 1251 patients. The combination of magnesium and beta-blocker did not significantly decrease the incidence of postoperative AA after CABG versus beta-blocker alone (odds ratio (OR) 1.12, 95% confidence interval (CI) 0.86-1.47, P = 0.40). Magnesium in addition to beta-blocker did not significantly affect LOS (weighted mean difference −0.14 days of stay, 95% CI −0.58 to 0.29, P = 0.24) or the overall mortality (OR 0.59, 95% CI 0.08-4.56, P = 0.62). However the risk of postoperative adverse events was higher in the combination of magnesium and beta-blocker group than beta-blocker alone (OR 2.80, 95% CI 1.66-4.71, P = 0.0001).

This meta-analysis offers the more definitive evidence against the prophylactic administration of intravenous magnesium for prevention of AA after CABG when beta-blockers are routinely administered, and shows an association with more adverse events in those people who received magnesium.

10 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atrial fibrillation (AF) is a frequent arrhythmia complicating cardiac surgery, and generally occurs within the first week after surgery. Although there are some etiological mechanisms to explain the postoperative AF, the exact mechanisms of AF are not well clarified. In the present study, we would like to show the effect of MgSO(4) infusion on P duration and P dispersion, and its relation with AF complication in patients undergoing coronary artery bypass grafting. The patients were randomly allocated into two groups. Group A consisted of 93 patients to whom 1.5 g/day MgSO(4) infusion in 100 mL 0.9 NaCl solution (25 mL/hr) were applied the day before surgery, just after operation, and once daily for 4 days following surgery. Group B consisted of 55 control patients to whom 100 mL 0.9 NaCl solution (25 mL/hr) were applied at the same time points. Magnesium level was measured before the treatment and daily for the postoperative four days. As a result, AF developed in 2% of cases in group A, and in 36% of cases in group B (p < 0.001). Comparing the patients who developed AF, and who did not, no difference was detected with regard to baseline P max, P min, P dispersion and fourth day P min. But fourth day P max and P dispersion of patients who developed AF were significantly higher than who did not. Baseline Mg level were similar for those who developed AF, and who did not, but fourth day Mg level was significantly lower in AF group. As a result, our opinion that Mg infusion significantly decreased the incidence AF after cardiac bypass surgery was confirmed. And it's also clear that beneficial effect of MgSO(4) is associated with its decreasing effect on P dispersion.
    Cardiac Electrophysiology Review 06/2003; 7(2):162-4. DOI:10.1111/j.1542-474X.2002.tb00165.x
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It has been suggested that the quality of clinical trials should be assessed by blinded raters to limit the risk of introducing bias into meta-analyses and systematic reviews, and into the peer-review process. There is very little evidence in the literature to substantiate this. This study describes the development of an instrument to assess the quality of reports of randomized clinical trials (RCTs) in pain research and its use to determine the effect of rater blinding on the assessments of quality. A multidisciplinary panel of six judges produced an initial version of the instrument. Fourteen raters from three different backgrounds assessed the quality of 36 research reports in pain research, selected from three different samples. Seven were allocated randomly to perform the assessments under blind conditions. The final version of the instrument included three items. These items were scored consistently by all the raters regardless of background and could discriminate between reports from the different samples. Blind assessments produced significantly lower and more consistent scores than open assessments. The implications of this finding for systematic reviews, meta-analytic research and the peer-review process are discussed.
    Controlled Clinical Trials 03/1996; 17(1):1-12. DOI:10.1016/0197-2456(95)00134-4
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Atrial fibrillation is a common complication of cardiovascular surgery. Beta-blockers have been shown to decrease the incidence of postoperative atrial fibrillation. However, the use of magnesium is more controversial. It was our hypothesis that adjunctive magnesium sulfate would improve the efficacy of beta-blockers alone in the prevention of postoperative atrial fibrillation. We prospectively randomized 167 coronary artery bypass patients (mean age 61+/-10 years, 115 men) to receive propranolol alone (20 mg four times daily) or propranolol and magnesium (18 g over 24 hours). Magnesium was begun intraoperatively, and propranolol was started on admission to the intensive care unit. Using an intention-to-treat analysis, the incidence of postoperative atrial fibrillation was 19.5% in the propranolol-treated patients and 22.4% in propranolol + magnesium-treated patients (p = 0.65). Because combination therapy resulted in an excess of postoperative hypotension, which required withholding doses of propranolol, an on-treatment analysis was also performed. In this analysis, the incidence of atrial fibrillation was still not significantly different (18.5% in propranolol-treated patients and 10.0% in propranolol + magnesium-treated patients, p = 0.20). Adjunctive magnesium sulfate, in combination with propranolol, does not decrease the incidence of postoperative atrial fibrillation.
    The Annals of Thoracic Surgery 02/2000; 69(1):126-9. DOI:10.1016/S0003-4975(99)01187-X · 3.85 Impact Factor
Show more

Preview (2 Sources)

10 Reads
Available from